Edwards Lifesciences (NYSE:EW) Issues Q2 2026 Earnings Guidance

Edwards Lifesciences (NYSE:EW) updated its second quarter 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.700-0.760 for the period, compared to the consensus EPS estimate of 0.750. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Edwards Lifesciences also updated its FY 2026 guidance to 2.950-3.050 EPS.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. TD Cowen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday, January 9th. Evercore reissued an “outperform” rating and set a $93.00 target price on shares of Edwards Lifesciences in a research report on Friday. BTIG Research increased their target price on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday. Barclays restated an “overweight” rating and issued a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a report on Monday, January 12th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $95.39.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $84.20 on Friday. The company has a market capitalization of $48.55 billion, a PE ratio of 46.01, a price-to-earnings-growth ratio of 2.08 and a beta of 0.95. The firm has a fifty day simple moving average of $81.71 and a 200-day simple moving average of $82.21. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a twelve month low of $72.30 and a twelve month high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts anticipate that Edwards Lifesciences will post 2.96 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $80.98, for a total transaction of $82,518.62. Following the completion of the transaction, the vice president directly owned 33,934 shares in the company, valued at approximately $2,747,975.32. This represents a 2.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the transaction, the chief financial officer owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. This trade represents a 24.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 86,058 shares of company stock worth $7,118,636. 0.31% of the stock is currently owned by company insiders.

Key Stories Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Q1 beat and raised FY26 outlook — Edwards reported adjusted EPS above consensus and roughly matched/beat revenue, then raised its FY26 EPS and sales guidance (EPS range $2.95–$3.05; sales growth guidance raised). This is the primary driver behind the stock rally. EW’s Q1 Earnings Beat, Revenues Match, ’26 View Up, Stock Climbs
• Positive Sentiment: Strong structural‑heart momentum and margin expansion — Management highlighted accelerating TAVR and TMTT growth, margin improvement and product momentum (including recent approvals), which supports higher longer‑term profitability expectations. Edwards Lifesciences beats quarterly estimates on robust demand for artificial heart valves
• Positive Sentiment: Capital return and buyback activity — Company disclosed a $500M accelerated share‑repurchase during the quarter, which supports EPS leverage and likely contributed to positive investor reaction. Edwards Lifesciences jumps 5.2% as Q1 results top expectations and full-year guidance rises
• Positive Sentiment: Analyst support — Some firms raised price targets/ratings (BTIG raised its target and reiterated buy), reinforcing bullish sentiment after the print. Price target / analyst notes
• Neutral Sentiment: Q2 guidance roughly in line — Q2 EPS guidance of $0.70–$0.76 sits around consensus, so the print is more notable for the FY lift than an outsized Q2 beat. Q1 earnings call highlights
• Neutral Sentiment: Mixed metric reporting from third parties — Some outlets show differing adjusted vs. GAAP EPS or alternate line‑item figures; these reconcileable reporting differences may cause short‑term noise. Q1 financial snapshot (third‑party)
• Negative Sentiment: Substantial insider selling — Public filings and aggregators show multiple insider sales (many executives selling shares) over recent months, which some investors interpret as a negative signal on near‑term insider conviction. Insider trading summary
• Negative Sentiment: Cost pressures — Cost of sales rose noticeably year‑over‑year (reported by some summaries), which could limit margin upside if the trend continues despite current operating margin gains. Cost / margin details

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently made changes to their positions in the business. Brighton Jones LLC bought a new position in Edwards Lifesciences during the fourth quarter worth $266,000. Zions Bancorporation National Association UT lifted its stake in Edwards Lifesciences by 114.8% during the fourth quarter. Zions Bancorporation National Association UT now owns 2,099 shares of the medical research company’s stock worth $179,000 after purchasing an additional 1,122 shares during the last quarter. Imprint Wealth LLC bought a new position in Edwards Lifesciences during the third quarter worth $108,000. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its stake in Edwards Lifesciences by 302.3% during the third quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 2,293 shares of the medical research company’s stock worth $178,000 after purchasing an additional 1,723 shares during the last quarter. Finally, Brown Brothers Harriman & Co. lifted its stake in Edwards Lifesciences by 20.9% during the third quarter. Brown Brothers Harriman & Co. now owns 1,893 shares of the medical research company’s stock worth $147,000 after purchasing an additional 327 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.